Prospective, Multicenter Feasibility Study to Evaluate Differential Target Multiplexed Spinal Cord Stimulation Programming in Subjects With Chronic Intractable Back Pain With or Without Leg Pain.

Differential Target Multiplexed programming axial low back pain chronic pain clinical outcomes neurostimulation spinal cord stimulation

Journal

Pain practice : the official journal of World Institute of Pain
ISSN: 1533-2500
Titre abrégé: Pain Pract
Pays: United States
ID NLM: 101130835

Informations de publication

Date de publication:
09 2020
Historique:
received: 08 04 2020
accepted: 26 04 2020
pubmed: 29 5 2020
medline: 22 12 2020
entrez: 29 5 2020
Statut: ppublish

Résumé

This prospective, open-label, multicenter study evaluated the feasibility of spinal cord stimulation (SCS) therapy programming for chronic low back pain that uses multiple electrical pulsed signals (Differential Target Multiplexed). Twenty-five SCS candidates with low back pain equal to or greater than lower limb pain were enrolled at 7 sites in the United States. The subjects evaluated standard and Differential Target Multiplexed programs, each for 4 ± 1 days. A commercially available SCS trial system was used for standard SCS therapy programming. During the trialing of the multiplexed programs, implanted temporary leads were connected to an investigational external trial stimulator system. Twenty subjects concluded the study. The mean baseline numeric pain rating scale (NPRS) score for low back pain was 7.4, with a mean age of 62.4 years and mean pain duration of 18.0 years. Significant relief in back pain was observed for both treatments, with significantly better response with multiplexed programming. At the end of the trial period, subjects reported a reduction in their mean NPRS score from baseline to 4.2 after standard programming and to 2.4 after Differential Target Multiplexed programming. The difference between standard and multiplexed programming was significant. The responder rate for low back pain relief was 50% for standard programming and 80% for Differential Target Multiplexed programming. Eighty-five percent of subjects who evaluated both programming approaches preferred Differential Target Multiplexed SCS. In this difficult-to-treat patient population, subjects reported significant reduction in chronic back pain when using multiplexed programming. A randomized clinical trial is needed to confirm the results from this feasibility study.

Identifiants

pubmed: 32462791
doi: 10.1111/papr.12908
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

761-768

Informations de copyright

© 2020 World Institute of Pain.

Références

Verrills P, Sinclair C, Barnard A. A review of spinal cord stimulation systems for chronic pain. J Pain Res. 2016;9:481-492.
Schade C, Sasaki J, Schultz DM, Tamayo N, King G, Johanek LM. Assessment of patient preference for constant voltage and constant current spinal cord stimulation. Neuromodulation. 2010;13:210-217.
Deer T, Slavin KV, Amirdelfan K, et al. Success Using Neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation. 2018;21:56-66.
Kapural L, Yu C, Doust MW, et al. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: the SENZA-RCT randomized controlled trial. Anesthesiology. 2015;123:851-860.
The National Institute for Health and Care Excellence. Senza Spinal Cord Stimulation (SCS) system for the treatment of chronic pain. 2017. https://www.nice.org.uk/guidance/gid-mt515/documents/assessment-report (accessed June 19, 2019)
Benyamin R, Galan V, Hatheway J, et al. Options: A prospective, open-label study of high-dose spinal cord stimulation in patients with chronic back and leg pain. Pain Physician. 2020;23:87-98.
Vallejo R, Kelley CA, Gupta A, Smith WJ, Vallejo A, Cedeño DL. Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Mol Pain. 2020;16:174480692091805.
Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicenter randomised controlled trial in patients with failed back surgery syndrome. Pain. 2007;132:179-188.
Tiede J, Brown L, Gekht G, Vallejo R, Yearwood T, Morgan D. Novel spinal cord stimulation parameters in patients with predominant back pain. Neuromodulation. 2013;16:370-375.
Van Buyten JP, Al-Kaisy A, Smet I, Palmisani S, Smith T. High-frequency spinal cord stimulation for the treatment of chronic back pain patients: results of a prospective multicenter European clinical study. Neuromodulation. 2013;16:59-65.
Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation: avoidance and treatment of complications of neurostimulation therapies for the treatment of chronic pain. Neuromodulation Appropriateness Consensus Committee. Neuromodulation. 2014;17:571-597.

Auteurs

Michael A Fishman (MA)

Center for Interventional Pain and Spine, Exton, Pennsylvania, U.S.A.

Aaron Calodney (A)

Precision Spine Care, Tyler, Texas, U.S.A.

Philip Kim (P)

Center for Interventional Pain and Spine, Exton, Pennsylvania, U.S.A.

Jan Slezak (J)

Interventional Spine Medicine, Barrington, New Hampshire, U.S.A.

Ramsin Benyamin (R)

Millennium Pain Center, Bloomington, Illinois, U.S.A.

Atiq Rehman (A)

Decatur Memorial Hospital, Decatur, Illinois, U.S.A.

Eliezer Soto (E)

Millennium Pain Center-Libertyville, Libertyville, Illinois, U.S.A.

Thomas Yang (T)

Swedish Medical Center, Seattle, Washington, U.S.A.

Asteghik Hacobian (A)

Interventional Spine Medicine, Barrington, New Hampshire, U.S.A.

Lee Griffith (L)

Precision Spine Care, Tyler, Texas, U.S.A.

Cong Yu (C)

Swedish Medical Center, Seattle, Washington, U.S.A.

Ricardo Vallejo (R)

Millennium Pain Center, Bloomington, Illinois, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH